BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 6455041)

  • 1. On the mechanism of action of progestins.
    Pérez-Palacios G; Fernández-Aparicio MA; Medina M; Zacarías-Villareal J; Ulloa-Aguirre A
    Acta Endocrinol (Copenh); 1981 Jul; 97(3):320-8. PubMed ID: 6455041
    [No Abstract]   [Full Text] [Related]  

  • 2. Pituitary response to LHRH in long-term users of injectable contraceptives.
    Ismail AA; el-Faras A; Rocca M; el-Sibai FA; Toppozada M
    Contraception; 1987 May; 35(5):487-95. PubMed ID: 2957167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
    Guerin JF; Rollet J
    Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations in pseudopregnant rats treated with medroxyprogesterone acetate.
    de Greef WJ; Dullaart J; Zeilmaker GH
    J Endocrinol; 1976 Sep; 70(3):465-71. PubMed ID: 978105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of contraceptive steroids on hypothalamic-pituitary function.
    Mishell DR; Kletzky OA; Brenner PF; Roy S; Nicoloff J
    Am J Obstet Gynecol; 1977 May; 128(1):60-74. PubMed ID: 403765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of climacteric and postmenopausal women with 17-beta-oestradiol and norethisterone acetate.
    Furuhjelm M; Carlström K
    Acta Obstet Gynecol Scand; 1977; 56(4):351-61. PubMed ID: 602703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Norethisterone enanthate as an injectable contraceptive in puerperal and non-puerperal women.
    Melis GB; Strigini F; Fruzzetti F; Paoletti AM; Rainer E; Düsterberg B; Fioretti P
    Contraception; 1981 Jan; 23(1):77-88. PubMed ID: 6781816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of contraceptive steroid formulations containing two doses of estrogen on pituitary function.
    Scott JZ; Kletzky OA; Brenner PF; Mishell DR
    Fertil Steril; 1978 Aug; 30(2):141-5. PubMed ID: 98356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment.
    Soufir JC; Jouannet P; Marson J; Soumah A
    Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting pituitary gonadotropin function in users of oral contraceptive steroids.
    Scott JA; Brenner PF; Kletzky OA; Mishell DR
    Am J Obstet Gynecol; 1978 Apr; 130(7):817-21. PubMed ID: 345817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.
    Hirvonen E; Mälkönen M; Manninen V
    N Engl J Med; 1981 Mar; 304(10):560-3. PubMed ID: 7453723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Return to ovulation following the use of long-acting injectable contraceptives: a comparative study.
    Garza-Flores J; Cardenas S; Rodríguez V; Cravioto MC; Diaz-Sanchez V; Perez-Palacios G
    Contraception; 1985 Apr; 31(4):361-6. PubMed ID: 3159544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunoassays of ethinyl-norgestrienone (R-2323) and medroxyprogesterone acetate (MPA) and their clinical applicability.
    Frick J; Bartsch G; Jakse G
    Urol Res; 1977; 5(2):55-9. PubMed ID: 69351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily serum follicle-stimulating hormone, luteinizing hormone, and plasma testosterone and androstenedione in hirsute women with polycystic sclerotic ovaries: effects of diethylstilbestrol and norethindrone acetats.
    Daane TA; Dignam WJ; Frankland MV; Simmer HH; Parlow AF
    Am J Obstet Gynecol; 1973 Oct; 117(3):392-9. PubMed ID: 4729733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of 19-nortestosterone-hexyloxyphenylpropionate (Anadur) and depot-medroxyprogesterone-acetate (Clinovir) for male contraception.
    Knuth UA; Yeung CH; Nieschlag E
    Fertil Steril; 1989 Jun; 51(6):1011-8. PubMed ID: 2524404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the potency of orally administered progestins in women.
    King RJ; Whitehead MI
    Fertil Steril; 1986 Dec; 46(6):1062-6. PubMed ID: 2946605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood hormone levels in egyptian women on norethisterone oenanthate.
    Saleh FM; Sallam HN; Abdel-Rahman H; Souka AR; El-Sahwi SY; Toppozada HK
    Contraception; 1983 Jul; 28(1):41-51. PubMed ID: 6414760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum norethindrone (NET) concentrations following intramuscular NET enanthate injection. Effect upon serum LH, FSH, estradiol and progesterone.
    Goebelsmann U; Stanczyk FZ; Brenner PF; Goebelsmann AE; Gentzschein EK; Mishell DR
    Contraception; 1979 Mar; 19(3):283-313. PubMed ID: 572279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.